Citation Impact
Citing Papers
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
2020 Standout
Quinolines and structurally related heterocycles as antimalarials
2010 Standout
Mechanism and medical implications of mammalian autophagy
2018 Standout
Interferon-Induced Sarcoidosis
2006
Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology
2020 Standout
Systemic lupus erythematosus
2016
Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review
2008 Standout
A cytokine-mediated link between innate immunity, inflammation, and cancer
2007 Standout
Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis
2017
Serum Levels of TNF‐α, IFN‐γ, IL‐6, IL‐8,IL‐12, IL‐17, and IL‐18 in Patients With Active Psoriasis andCorrelation With Disease Severity
2005 Standout
Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus
2005
B-cell inhibitors as therapy for rheumatoid arthritis: An update
2007
Quinoline Antimalarials Mechanisms of Action and Resistance and Prospects for New Agents
1998
IL-6 in autoimmune disease and chronic inflammatory proliferative disease
2002
Efficacy of a New Tonic Containing Urea, Lactate, Polidocanol, and <b><i>Glycyrrhiza inflata</i></b> Root Extract in the Treatment of a Dry, Itchy, and Subclinically Inflamed Scalp
2013 Standout
Graves' Ophthalmopathy
2010 Standout
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm
2017 Standout
Systemic Lupus Erythematosus
2011 Standout
Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV
2005
The trinity of COVID-19: immunity, inflammation and intervention
2020 Standout
Abnormal T cell signal transduction in systemic lupus erythematosus
2002
The role of antimalarial agents in the treatment of SLE and lupus nephritis
2011
Autophagy: controlling cell fate in rheumatic diseases
2016
Sarcoidosis
2007 Standout
Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues
2019
State of Evidence on the Relationship between High-Volume Hospitals and Outcomes in Surgery: A Systematic Review of Systematic Reviews
2013
The role of IL-6 and STAT3 in inflammation and cancer
2005 Standout
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Strain-Specific Manifestation of Lupus-like Systemic Autoimmunity Caused by Zap70 Mutation
2019 StandoutNobel
The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults
2017
Works of DJ Wallace being referenced
Volume-outcome relationship in critical care: a systematic review
2012
Association of IL-6 gene alleles with systemic lupus erythematosus (SLE) and with elevated IL-6 expression
1999
The history of antimalarials
1996
Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus
2012
Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years
2009
The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review
1996
The importance of implementing proper selection of excipients in lupus clinical trials
2014
High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus
2011
OP0184 Efficacy and Safety of Tabalumab in Patients with Systemic Lupus Erythematosus (SLE): Results from 2 Phase 3, 52-Week, Multicenter, Randomized, Placebo-Controlled Trials
2015
TRU-015, a small modular immunopharmaceutical (SMIP™) drug candidate directed against CD20, demonstrates clinical improvement in subjects with rheumatoid arthritis
2007